.jpg)
1 hour ago
3
Article content
- Financing led by Investissement Québec with continued support from long-standing investors
- Plans include the acceleration of clinical development of breakthrough GPCR targeting treatments for patients
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
MONTREAL and STRASBOURG, France and BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) — Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close of its Series B financing round totaling $32 million CAD. This financing round was led by Investissement Québec and was supported by existing investors CTI Life Sciences, Panacea Venture, 3B Future Health Fund, Seventure Partners, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare BioInnovations, and Seido Capital.
Article content
Article content
Article content
The investment demonstrates strong confidence in Kainova Therapeutics’ strategic direction and supports the clinical advancement of its GPCR-targeting therapies. Lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is progressing in the ongoing Phase I/II DOMISOL trial for the treatment of solid tumors. The Company is also advancing other GPCR-targeting therapies, including DT-9081, an EP4 antagonist for solid tumors and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory conditions, further positioning Kainova Therapeutics as a leader in global precision medicine.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics, said: “I am delighted to welcome Investissement Québec as a new investor in the Company and deeply appreciate the continued commitment from our investors. This financing is a strong endorsement of our distinctive scientific strategy, our leadership in GPCR innovation, and our well-defined pipeline of high-value programs with significant commercial potential. Securing this investment is especially significant given the current challenging fundraising environment, but exceptional science is still rewarded, and Kainova Therapeutics remains focused on advancing its robust clinical pipeline of GPCR targeting therapies and delivering breakthrough treatments for patients worldwide.”
Article content
Article content
Laurence Rulleau, Chair of the Board, and Managing Partner, CTI Life Sciences Fund, commented: “This financing marks a crucial moment in the realization of Kainova Therapeutics’ clinical roadmap and corporate growth. The team achieved significant clinical milestones during 2025, positioning the company at the forefront of GPCR innovation and demonstrating potential of value creation. We look forward with enthusiasm and are pleased to welcome Investissement Québec and Louis-Etienne Fortier to the Board of Directors to achieve the Company’s potential and vision of transforming patients’ lives.”
Article content
Bicha Ngo, President and Chief Executive Officer of Investissement Québec, added: “Investissement Québec is pleased to support the research and development of innovative solutions in a critical industry like life sciences. Through our participation in this significant financing effort, we are contributing to the relocation of the Company’s headquarters to Québec and laying the groundwork for a team with unique expertise in pharmaceutical development. Working in cooperation with the team at Kainova Therapeutics, we will deliver essential support to drive growth and foster further innovation.”
English (US)